Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

Fig. 2

Evolution of pharmacological groups. (A) Global Series. (B) De Novo without previous heart disease. (C) De Novo with previous heart disease. (D) Non-de novo

Percentage of patients with a prescription at discharge in the study drug groups. Blue line: RAASi, orange line: MRA, yellow line: Bb, purple line: SGLT2i. Dashed lines: linear trends

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us